SABS
SAB Biotherapeutics·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Growth
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SABS
Sab Biotherapeutics, Inc.
A clinical-stage biopharmaceutical company engages in advancing immunotherapies leveraging human polyclonal antibodies
Biological Technology
11/12/2020
02/09/2021
NASDAQ Stock Exchange
63
12-31
Common stock
2100 East 54th Street North, Sioux Falls, South Dakota 57104
--
SAB Biotherapeutics, Inc., was incorporated in Delaware on November 12, 2020. The company is a clinical-stage biopharmaceutical company that uses fully human polyclonal antibodies to advance a new class of immunotherapies. SAB has applied advanced genetic engineering and antibody science to develop a transchromosomal (Tc) Bovine herd that can produce fully human antibodies against specific diseases, including infectious diseases such as COVID - 19 and influenza, immune system diseases such as type 1 diabetes and organ transplantation, and cancer. SAB's multifunctional DiversitAb platform is suitable for a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, highly effective human polyclonal immunotherapy. SAB is currently advancing several clinical programs and working with the US government and global pharmaceutical companies.
Company Financials
EPS
SABS has released its 2025 Q3 earnings. EPS was reported at -0.21, versus the expected -0.46, beating expectations. The chart below visualizes how SABS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
